MoonLake Immunotherapeutics MLTX
11.70 USD +0.23 (+2.01%)
At closeNov 3, 2026, 6:31 PM EST
11.70 0.00 0.00%
After hours · Nov 3, 6:31 PM ET
11.29 Day range 11.72
9.46 52-week range 23.29
- YTD
- -11.23%
- 1 year
- +14.71%
Financial health
Altman Z-Score
2.26 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 2
- P/E 1
- P/B 2
Valuation
P/E -3.7×
FY 2020 5y median -6.8× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 2.8×
FY 2020 5y median 6.0× FY 2025
P/FCF -4.3×
FY 2020 5y median -10.4× FY 2025
EV/EBITDA -2.7×
FY 2020 5y median -6.9× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -23.1%
FY 2020 5y median -9.6% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -74.7%
FY 2020 5y median -26.6% FY 2025
ROIC -64.4%
FY 2020 5y median -64.4% FY 2025
ROA -53.6%
FY 2020 5y median -53.6% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -71.1%
FY 2020 FY 2025
EPS (diluted) -86.8%
FY 2020 FY 2025
Free Cash Flow -67.4%
FY 2020 FY 2025
Financial Health
Current Ratio 9.3×
FY 2020 5y median 10.0× FY 2025
Quick Ratio 9.3×
FY 2020 5y median 10.0× FY 2025
Debt / Equity 0.2×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 1.2×
FY 2020 5y median 1.2× FY 2025
Interest Coverage -33.8×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31